Want to see SLSN full AI Analyst Report?
SLSN Stock Chart & Stats
$2.17
--
Market closed
$2.17
--
Day’s Range― - ―
52-Week Range$0.70 - $4.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)50.43K
Market Cap
$51.91M
Enterprise Value$112.12M
Total Cash (Recent Filing)$573.00K
Total Debt (Recent Filing)$22.28M
Price to Earnings (P/E)48.2
Beta1.72
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding70,632,450
10 Day Avg. Volume39,901
30 Day Avg. Volume50,427
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)6.38
Price to Sales (P/S)1.81
P/FCF Ratio-10.51
Enterprise Value/Market Cap2.16
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit7.01
Enterprise Value/Ebitda37.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StabilizationMaterial deleveraging and a stronger equity base reduce refinancing risk and increase financial flexibility. This stabilization gives management runway to fund Transform & Transcend initiatives, absorb execution hiccups, and invest in capacity or R&D without immediate equity raises.
Proprietary Product InnovationNew proprietary formulations broaden addressable markets (e.g., SPF-infused hybrids, hair/scalp adjacencies) and strengthen differentiation versus commodity suppliers. Sustained product innovation supports pricing power, customer stickiness, and long-term brand partnerships.
Strong Forward Orders & Growth RecordA sizable shipped and open orders book indicates durable commercial demand and near-term revenue visibility. Combined with a multi‑year high CAGR and completed co-marketing deals, this supports scaling benefits and better capacity utilization as operational improvements take hold.
Bears Say
Weak Cash GenerationPersistently negative free cash flow and volatile operating cash flows constrain internal funding for capex, working capital and strategic initiatives. Continued weak cash generation increases reliance on external financing, raising dilution or interest burden risk over the medium term.
Compressed Margins & Revenue SoftnessSharp margin compression and modest top-line decline reduce earnings resilience and leave less room to fund investments or weather cost inflation. Achieving management's target of double-digit EBITDA requires sustained margin recovery and revenue stability, currently uncertain.
Execution And Supply RisksOperational disruptions and implementation complexity (SIOP, shift changes, consolidation) have already depressed revenue and profitability. Execution risk is structural while processes are retooled, threatening delivery reliability, customer relationships, and timely realization of projected savings.
Solesence News
SLSN FAQ
What was Solesence’s price range in the past 12 months?
Solesence lowest stock price was $0.70 and its highest was $4.55 in the past 12 months.
What is Solesence’s market cap?
Solesence’s market cap is $51.91M.
When is Solesence’s upcoming earnings report date?
Solesence’s upcoming earnings report date is Aug 18, 2026 which is in 48 days.
How were Solesence’s earnings last quarter?
Currently, no data Available
Is Solesence overvalued?
According to Wall Street analysts Solesence’s price is currently Overvalued.
Does Solesence pay dividends?
Solesence does not currently pay dividends.
What is Solesence’s EPS estimate?
Solesence’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solesence have?
Solesence has 70,632,450 shares outstanding.
What happened to Solesence’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Solesence?
Currently, no hedge funds are holding shares in SLSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solesence Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
10.50%
Trailing 12-Months
Asset Growth
0.11%
Trailing 12-Months
Company Description
Solesence
Solesence, Inc., formerly known as Nanophase Technologies Corporation, specializes in the development and production of clean-label, inclusive, and mineral-based skincare and cosmetic products. The company collaborates with a diverse range of partners, from major global corporations to independent brands, employing its unique Active Stress Defense™ technology suite. Through this proprietary system, Solesence brings innovative beauty solutions to the market that provide effective environmental protection.
SLSN Company Deck
SLSN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: near-term financial results were pressured by shipment delays and investments tied to the Transform and Transcend initiative (revenue down ~11%, net loss and negative adjusted EBITDA), but key positives include a 300-basis-point gross margin improvement to 26%, a $47M shipped + open orders book, new proprietary technology launches (Chromalum and WHSPR), completed co-marketing activations with brand partners, and a clear operational roadmap (SIOP, shift changes, facility consolidation) with reiterated guidance including a 30% gross profit floor and a plan to return to double-digit EBITDA margins by year-end. Given the balance of material execution risks and encouraging operational and commercial progress, the tone is cautiously optimistic but transitional.View all SLSN earnings summariesTechnical Analysis
Ownership Overview
5.91% Insiders
2.03% Mutual Funds
0.05% Other Institutional Investors
90.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---